As Informa Pharma Intelligence has done for the past three years, this analysis examines the landscape of industry-sponsored clinical trials completed during 2017, of which there were a total of 3,534 Phase I through Phase III/IV. The nearly 700 trials terminated in 2017 were not included in this analysis.
This year’s metric is comparable to what was reported for 2016 completions (3,420 trials) and for 2015 (3,028 trials). At the therapeutic area level, 2017 completed trials in oncology again dominated, with 910 trials, and type 2 diabetes was the disease with the largest number of completed trials, at 171. Who surpassed Novartis to become the top sponsor in 2017? As was reported for the previous year, 2017 also saw a significant volume of industry partnering for trials. Download now to find out more!